• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEIJI PHARMA SPAIN S.A GENVISC850 ACID, HYALURONIC, INTRAARTICULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEIJI PHARMA SPAIN S.A GENVISC850 ACID, HYALURONIC, INTRAARTICULAR Back to Search Results
Model Number 50653-0006-01
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Bacterial Infection (1735)
Event Date 05/21/2022
Event Type  Injury  
Event Description
(b)(6) 2022 the clinic reported the adverse event to orthogenrx who reported it to the genvisc850 call center that a female patient was hospitalized on (b)(6) 2022 for treatment after receiving a genvisc 850 bilateral knee injections on (b)(6) 2022. The patient's medical history includes osteoarthritis with 3 rounds of genvisc850 over many previous years with improvement in mobility/pain. The patient received the 1st bilateral genvisc850 intraarticular knee injection on (b)(6) 2022 for this round of injections. Lidocaine was administered for comfort and omnipaque for the fluoroscopy for the correct placement of the injections. On (b)(6) 2022 the patient went to the hospital with increased pain radiating down her leg. At the hospital the patient had a knee wash-out procedure and was started on iv antibiotics. A culture was done indicating the present of a staph infection. The antibiotics were changed (b)(6) 2022 to vancomycin and a cephalosporin antibiotic. The clinic contact indicated the patient is doing fine. This case is serious and the genvisc850 or the administration procedure including the lidocaine and omnipaque cannot be excluded. Ap (b)(6) 2022 from orthogenrx: lot r-1 finished product release certificate indicates product sterility. Ap. (b)(6) 2022 meiji spain's comment: this case has been tagged as serious requiring hospital treatment and longer hospital stay and it cannot be discerned if the genvisc850 or the administration procedure including the lidocaine and omnipaque are responsible. However, the lack of issues in the batch used and the lack of specific information on the antiseptic approach use might pinpoints to the injection procedure followed. (b)(6) 2022 orthogenrx comment: genvisc850 lot r-1, consisting of (b)(6) units, was released for distribution on 14-apr-2021. All units were distributed from orthogenrx control by (b)(6) 2021. No other reports of infections have been received for this lot. Meiji pharma spain certifies that this batch has been manufactured and analyzed in full compliance with the gmp, the local regulation and specifications and requirements of the marketing authorization. Uploaded lot r-1 finished product release certificate indicating product sterility to case file. (b)(6) 2021 the contact updated the ae of this case. He said they no longer suspect genvisc850 was contributory to the ae due to another incident unrelated to genvisc850. They believe the cause of this ae of infection likely to be the multiuse vials of lidocaine and omnipaque. They did not retain the multiuse vials of lidocaine and omnipaque so no cultures of these products were done. He is reporting the adverse events to these product companies as well. Ap.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameGENVISC850
Type of DeviceACID, HYALURONIC, INTRAARTICULAR
Manufacturer (Section D)
MEIJI PHARMA SPAIN S.A
avda. de madrid, 94
28802 alcalá de henares
madrid,
SP
Manufacturer (Section G)
MEIJI PHARMA SPAIN,S.A.
avda.de madrid 94
28802 alcalá de henares
madrid,
SP
Manufacturer Contact
clara prieto
avda. de madrid 94
28802 alacala de henares
madrid, 
SP  
MDR Report Key14697018
MDR Text Key294944206
Report Number3003184440-2022-00002
Device Sequence Number1
Product Code MOZ
UDI-Device Identifier00850653006016
UDI-Public(01)00850653006016(17)240131(10)R1
Combination Product (y/n)Y
Reporter Country CodeUS
PMA/PMN Number
PMA P140005
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional
Reporter Occupation Administrator/Supervisor
Type of Report Initial
Report Date 05/23/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received06/15/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator
Device Model Number50653-0006-01
Device Lot NumberR-1
Was Device Available for Evaluation? No
Date Manufacturer Received05/23/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured01/08/2021
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial

Patient Treatment Data
Date Received: 06/15/2022 Patient Sequence Number: 1
Treatment
LIDOCAINE; OMNIPAQUE
-
-